{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T10:52:55Z","timestamp":1744368775210},"reference-count":9,"publisher":"Cambridge University Press (CUP)","issue":"4","license":[{"start":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T00:00:00Z","timestamp":1637712000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cambridge.org"],"crossmark-restriction":true},"short-container-title":["Infect. Control Hosp. Epidemiol."],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We assessed trends in treatment of patients with CRE from 2012 through 2018. We detected decreased utilization of aminoglycosides and colistin and increased utilization in extended-spectrum cephalosporins and ceftazidime-avibactam. We found significant uptake of ceftazidime-avibactam, a newly approved antibiotic, to treat CRE infections.<\/jats:p>","DOI":"10.1017\/ice.2021.452","type":"journal-article","created":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T04:11:28Z","timestamp":1637727088000},"page":"674-677","update-policy":"http:\/\/dx.doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":2,"title":["Uptake in newly approved antibiotics prescribed to patients with carbapenem-resistant Enterobacterales (CRE)"],"prefix":"10.1017","volume":"44","author":[{"given":"Katie J.","family":"Suda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Traversa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ursula","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Poggensee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret A.","family":"Fitzpatrick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geneva M.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlesnika T.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2021,11,24]]},"reference":[{"key":"S0899823X21004529_ref4","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz344"},{"key":"S0899823X21004529_ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s12941-018-0267-8"},{"key":"S0899823X21004529_ref5","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa061"},{"key":"S0899823X21004529_ref8","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix783"},{"key":"S0899823X21004529_ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s13756-018-0346-9"},{"key":"S0899823X21004529_ref6","unstructured":"6. Infectious Diseases Society of America. Infectious Diseases Society of America guidance on the treatment of antimicrobial resistant gram-negative infections. https:\/\/www.idsociety.org\/practice-guideline\/amr-guidance\/. Published 2020. Accessed November 4. 2021."},{"key":"S0899823X21004529_ref3","first-page":"403","article-title":"Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant","volume":"8","author":"Thaden","year":"2017","journal-title":"Enterobacteriaceae."},{"key":"S0899823X21004529_ref9","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa651"},{"key":"S0899823X21004529_ref1","unstructured":"1. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. Centers for Disease Control and Prevention website. https:\/\/www.cdc.gov\/drugresistance\/pdf\/ar-threats-2013-508.pdf. Accessed September 5, 2019."}],"container-title":["Infection Control &amp; Hospital Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0899823X21004529","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T09:02:39Z","timestamp":1681290159000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0899823X21004529\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,24]]},"references-count":9,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S0899823X21004529"],"URL":"https:\/\/doi.org\/10.1017\/ice.2021.452","relation":{},"ISSN":["0899-823X","1559-6834"],"issn-type":[{"value":"0899-823X","type":"print"},{"value":"1559-6834","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,24]]},"assertion":[{"value":"\u00a9 The Author(s), 2021. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America","name":"copyright","label":"Copyright","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http:\/\/creativecommons.org\/licenses\/by\/4.0\/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}